TY  - GEN
AB  - Pancreatic Ductal Adenocarcinoma (PDAc) ranks among the top three most aggressive cancers in the United States and is projected to increase in incidence over the next few years. Standard-of-care (SoC) treatment for PDAc consists of a cocktail of harsh chemotherapies, which have improved overall survival by only a few percentage points—to a 5-year survival rate of 13%. This dismal prognosis is a result of its primarily late-stage diagnosis and lack of durable response to treatment, the latter of which is partially due to PDAc’s desmoplastic and immunosuppressive microenvironment. This dissertation will demonstrate the potential of both the novel KMCERT2 mouse model and 3D-bioprinting to improve our understanding of pancreatic cancer progression and treatment response, ultimately leading to more effective therapies for patients.
AD  - Oregon Health and Science University
AU  - English, Isabel
DA  - 2024-09-20
DO  - 10.6083/bpxhc43714
DO  - doi
ED  - Sears, Rosalie
ED  - Langer, Ellen
ED  - McCullough, Amanda
ED  - Moran, Amy
ED  - Grossberg, Aaron
ED  - Sherman, Mara
ED  - Byrne, Katelyn
ED  - Co-Mentor
ED  - Co-Mentor
ED  - Chair
ED  - Committee member
ED  - Committee member
ED  - Committee member
ED  - Committee member
ID  - 43714
KW  - Pancreatic Neoplasms
KW  - Bioprinting
KW  - Mice, Transgenic
KW  - Pancreas
KW  - Genetic Heterogeneity
KW  - MYC
KW  - PDAC
KW  - cancer
KW  - preclinical modeling
KW  - GEMM
L1  - https://digitalcollections.ohsu.edu/record/43714/files/English.Isabel.2024.pdf
L2  - https://digitalcollections.ohsu.edu/record/43714/files/English.Isabel.2024.pdf
L4  - https://digitalcollections.ohsu.edu/record/43714/files/English.Isabel.2024.pdf
LA  - eng
LK  - https://digitalcollections.ohsu.edu/record/43714/files/English.Isabel.2024.pdf
N2  - Pancreatic Ductal Adenocarcinoma (PDAc) ranks among the top three most aggressive cancers in the United States and is projected to increase in incidence over the next few years. Standard-of-care (SoC) treatment for PDAc consists of a cocktail of harsh chemotherapies, which have improved overall survival by only a few percentage points—to a 5-year survival rate of 13%. This dismal prognosis is a result of its primarily late-stage diagnosis and lack of durable response to treatment, the latter of which is partially due to PDAc’s desmoplastic and immunosuppressive microenvironment. This dissertation will demonstrate the potential of both the novel KMCERT2 mouse model and 3D-bioprinting to improve our understanding of pancreatic cancer progression and treatment response, ultimately leading to more effective therapies for patients.
PB  - Oregon Health and Science University
PY  - 2024-09-20
T1  - Bridging the gap between preclinical models and clinical trials using a novel Kras- and Myc-driven mouse model of pancreatic cancer and 3D-bioprinting
TI  - Bridging the gap between preclinical models and clinical trials using a novel Kras- and Myc-driven mouse model of pancreatic cancer and 3D-bioprinting
UR  - https://digitalcollections.ohsu.edu/record/43714/files/English.Isabel.2024.pdf
Y1  - 2024-09-20
ER  -